Android app on Google Play

Targacept (TRGT) Higher After Positive TC-5214 Trial For Major Depressive Disorder

October 16, 2009 8:22 AM EDT Send to a Friend
Targacept, Inc. (NASDAQ: TRGT) is indicated to open higher today after announcing data from its recently completed Phase 2b clinical trial of TC-5214 as an augmentation (add-on) treatment in subjects with major depressive disorder, or MDD, who did not respond adequately to first-line treatment with the representative SSRI citalopram hydrobromide. In the trial, the add-on TC-5214 arm (TC-5214 + citalopram) outperformed the add-on placebo arm (placebo + citalopram) on the primary outcome measure, the Hamilton Rating Scale for Depression-17, or HAM-D, and all of the secondary outcome measures, with high statistical significance.

In the TC-5214 trial, the magnitude of clinical response (change from double blind baseline after eight weeks) on HAM-D was 6.0 points greater for the add-on TC-5214 arm (13.75 point improvement) than for the add-on placebo arm (7.75 point improvement). This result was highly statistically significant (p < 0.0001) on an intent to treat basis. Highly statistically significant results (p < 0.0001) were also achieved on an intent to treat basis on all of the trial’s secondary outcome measures, including the Montgomery-Asberg Depression Rating Scale, or MADRS, the Quick Inventory of Depressive Symptomatology – Self Reporting scale and assessments of irritability, disability, cognition, severity of illness and global improvement. As previously reported, TC-5214 exhibited a favorable tolerability profile in the trial.

A number of analysts have come out positive on Targacept following the results. Needham upgraded the stock to Buy, calling the treatment a potential blockbuster.



You May Also Be Interested In


Related Categories

FDA, Momentum Movers

Related Entities

Needham & Company

Add Your Comment